| [1] |
Jain RK. Antiangiogenesis strategies revisted: from starving tumors to alleviating hypoxia[J]. Cancer Cell, 2014,26(5):605-622. DOI: 10.1016/j.ccell.2014.10.006.
doi: 10.1016/j.ccell.2014.10.006
|
| [2] |
Nie J, Wang C, Liu Y, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma[J]. J Clin Oncol, 2019,37(17):1479-1489. DOI: 10.1200/JCO.18.02151.
doi: 10.1200/JCO.18.02151
pmid: 31039052
|
| [3] |
Song Y, Wu J, Chen X, et al. A single-arm multicenter, phase Ⅱ study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma[J]. Clin Cancer Res, 2019,25(24):7363-7369. DOI: 10.1158/1078-0432.CCR-19-1680.
doi: 10.1158/1078-0432.CCR-19-1680
pmid: 31420358
|
| [4] |
Xu J, Zhang Y, Jia R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophago-gastric iunction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019,25(2):515-523. DOI: 10.1158/1078-0432.CCR-18-2484.
doi: 10.1158/1078-0432.CCR-18-2484
pmid: 30348638
|
| [5] |
Huang J, Mo H, Zhang W, et al. Promising efficacy of SHR-1210, a noval anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China[J]. Cancer, 2019,125(5):742-749. DOI: 10.1002/cncr.31855.
pmid: 30508306
|
| [6] |
Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018,24(6):1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439.
pmid: 29358502
|
| [7] |
Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018,19(10):1338-1350. DOI: 10.1016/s1470-2045(18)30495-9.
doi: 10.1016/S1470-2045(18)30495-9
pmid: 30213452
|
| [8] |
Hause RJ, Pritchard CC, Shendure J, et al. Classification and characterization of microsatellite instability across 18 cancer types[J]. Nat Med, 2016,22(11):1342-1350. DOI: 10.1038/nm.4191.
pmid: 27694933
|
